A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China

• Published in: BMC medicine Vol. 22; no. 1; pp. 142 - 11
• Main Authors: Wang, Ying, Wu, Depei, Zhang, Xiang, Li, Yuhua, He, Yanjie, Liu, Qifa, Xuan, Li, Li, Zhenyu, Qi, Kunming, Sun, Yuqian, Wang, Shunqing, Mo, Wenjian, Gao, Lei, Hua, Ye, Wang, Yu, Zhang, Ying
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26.03.2024; BioMed Central; BMC
• Subjects: Acetamides; Adrenal Cortex Hormones - therapeutic use; Belumosudil; Binomial distribution; Bronchiolitis Obliterans Syndrome; Calcineurin inhibitors; Care and treatment; cGVHD; China; Chronic Disease; Complications and side effects; Corticoids; Corticosteroids; Cytokines; Dosage and administration; Efficacy; Enrollments; Graft versus host disease; Graft versus host reaction; Graft vs Host Disease; Hematopoietic stem cells; Humans; Hypothesis testing; Informed consent; Kinases; Mortality; Patients; Pharmacokinetics; Phosphorylation; Population; Response rates; ROCK; ROCK2 inhibitor; Safety; Signs and symptoms; Stem cell transplantation; Stem cells; Steroids; Survival; Therapy; Toxicity; Transplantation; China; United States > US; ROCK2 inhibitor; Belumosudil; ROCK; China; Efficacy; cGVHD; Safety

Chronic graft-versus-host disease (cGVHD) is an immune-related disorder that is the most common complication post-allogenic hematopoietic stem cell transplant. Corticosteroids with or without calcineurin inhibitors (CNIs) remain the mainstay of cGVHD treatment for first-line therapy. However, for ma...